An overview of drug development in the United States and current challenges
- PMID: 14696877
- DOI: 10.1097/01.SMJ.0000102285.48482.C9
An overview of drug development in the United States and current challenges
Abstract
Drug development in the United States has undergone many changes in the past 25 years, but relatively few fully realize the complexities involved in developing a new drug. Once a promising compound is identified, it must undergo preclinical testing, have an Investigational New Drug Application filed with the U.S. Food and Drug Administration (FDA), and proceed through clinical testing. When sufficient information is gained, a marketing application is filed with the FDA, who identifies it as a New Drug Application for drugs or a Biologics License Application for biologics. After FDA review and approval, postmarketing studies are frequently performed. The FDA and Congress have undertaken several initiatives to expand access and to accelerate drug development and review of investigational drugs for life-threatening and/or serious illnesses. Although the ultimate goal is to bring safer and more effective medical products to patients in a timely manner, multiple challenges face those who participate in drug development.
Similar articles
-
How drugs are developed and approved by the FDA: current process and future directions.Am J Gastroenterol. 2014 May;109(5):620-3. doi: 10.1038/ajg.2013.407. Am J Gastroenterol. 2014. PMID: 24796999 Review.
-
FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.Food Drug Law J. 2009;64(1):183-223. Food Drug Law J. 2009. PMID: 19998746
-
Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.Gastroenterol Clin North Am. 2006 Dec;35(4):735-41. doi: 10.1016/j.gtc.2006.09.010. Gastroenterol Clin North Am. 2006. PMID: 17129810 Review.
-
Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.Semin Nucl Med. 2010 Sep;40(5):364-84. doi: 10.1053/j.semnuclmed.2010.05.002. Semin Nucl Med. 2010. PMID: 20674596 Review.
-
How are drugs approved? Part 1: the evolution of the Food and Drug Administration.J Psychosoc Nurs Ment Health Serv. 2008 Jan;46(1):15-9. doi: 10.3928/02793695-20080101-06. J Psychosoc Nurs Ment Health Serv. 2008. PMID: 18251347 Review.
Cited by
-
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798. Epub 2020 Dec 24. Pharmacol Ther. 2021. PMID: 33359599 Free PMC article. Review.
-
Reframing person-centered nursing care for persons with dementia.Res Theory Nurs Pract. 2007;21(1):57-72. doi: 10.1891/rtnpij-v21i1a007. Res Theory Nurs Pract. 2007. PMID: 17378465 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
